OraSure Technologies, Inc. (OSUR) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed outlook. While revenue and margins are stable, significant challenges include declining international diagnostics revenue and economic uncertainties. The positive aspects include operational efficiencies, innovation investments, and a share repurchase program. The Q&A provides a strategic fit for acquisitions and improved gross margins, but risks like regulatory approvals and market conditions persist. Overall, the sentiment is balanced, suggesting a neutral stock price movement.
Key Financial Performance
Total Revenue $27.1 million, core revenue was $27.0 million. Diagnostics revenue was $14.5 million and Sample Management revenue was $10.3 million. Reasons for changes include mixed key end markets and elevated levels of uncertainty related to funding for public health programs and research.
International Diagnostics Business Revenue Expected to be in the low to mid-$30 million range for the full year 2025, representing a decline of approximately 20% compared to 2024. The decline is due to a slower pace of orders for HIV tests as in-country partners work through existing inventory and adapt to changes in the funding environment.
U.S. Diagnostics Business Revenue Expected to generate revenue in the low to mid-$30 million range for the full year 2025, representing a low single-digit percentage decline compared to 2024. The decline is attributed to reductions in staffing at federal agencies and budgetary uncertainty.
Sample Management Products Revenue Expected to be in the high $30 million range for the full year 2025, approximately flat compared to 2024, excluding the impact of the decline in orders from a large consumer genetics customer.
GAAP Gross Margin 43.5% in Q3, with a non-GAAP gross margin of 44.2%. Slightly better than expectations due to lower scrap expenses.
GAAP Operating Expenses $27.9 million in Q3, including $2.8 million of noncash stock compensation expense and $376,000 of expense related to an increase in the estimated fair value of acquisition-related contingent consideration.
GAAP Operating Loss $16.1 million in Q3, with a non-GAAP operating loss of $12.7 million.
Cash and Cash Equivalents $216 million at the end of Q3. Operating cash flow in Q3 was negative $10 million, consistent with Q2 and expectations due to investments in innovation projects.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Sickle SCAN: Acquisition of BioMedomics to expand diagnostic portfolio with Sickle SCAN, a rapid test for sickle cell disease, targeting underserved markets in Africa and Latin America.
Colli-Pee device: Plans to submit clinical trial data to FDA for STI indications by late 2025 or early 2026, aiming to strengthen competitive position in urine collection.
Sherlock Molecular Diagnostics Rapid Test: Progress in clinical trials for CT/NG assay, with FDA submission planned for late 2025 or early 2026.
HEMAcollect PROTEIN: Launched in July 2025 for proteomics research, receiving positive feedback and aiming for further momentum in 2026.
International Diagnostics: Revenue expected to decline by 20% in 2025 due to slower orders for HIV tests and changes in funding environment.
U.S. Diagnostics: Revenue expected to decline slightly in 2025, with growth in nonpublic health markets like urgent care and online consumer testing.
Sample Management: Revenue expected to remain flat in 2025, with growth anticipated in 2026 driven by genomic advancements and international market investments.
Cost productivity: Delivered cost productivity at both business and product levels.
Cash flow profile: Strengthened cash flow profile while maintaining a strong balance sheet to support innovation investments.
Acquisition of BioMedomics: Strategic acquisition to enhance diagnostic capabilities and expand into underserved markets.
Innovation pipeline: Investments in internal R&D and M&A to drive growth in diagnostics, STIs, and liquid biopsy markets.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Market Conditions: Key end markets remain mixed, with elevated levels of uncertainty related to funding for public health programs and research, as well as the government shutdown in the U.S.
International Diagnostics Revenue Decline: Revenue from the International Diagnostics business is expected to decline by approximately 20% in 2025 compared to 2024 due to slower pace of orders for HIV tests and changes in the funding environment.
U.S. Public Health Challenges: Public health customers in the U.S. are facing significant reductions in staffing at federal agencies like HHS, CDC, and SAMHSA, along with budgetary uncertainty and challenges related to the federal government shutdown.
Sample Management Business: The Sample Management business is experiencing mixed trends, with a sequential decline in Q4 expected due to seasonal ordering patterns and a decline in orders from a large consumer genetics customer.
Regulatory and Product Development Risks: Several product innovations, including Colli-Pee and Sherlock Molecular Diagnostics Rapid Test platform, are awaiting FDA approvals, which could impact timelines and market entry.
Economic Uncertainties: Investments in innovation and acquisitions, such as the Sherlock platform and BioMedomics, are contributing to operating losses and negative cash flow, with potential risks if expected returns are not realized.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance for International Diagnostics: Revenue from International Diagnostics business is expected to be in the low to mid-$30 million range for 2025, representing a decline of approximately 20% compared to 2024.
Revenue Guidance for U.S. Diagnostics: Revenue for the U.S. Diagnostics business is projected to be in the low to mid-$30 million range for 2025, representing a low single-digit percentage decline compared to 2024.
Revenue from Together Take Me Home Program: The program is expected to generate approximately $1.8 million in Q4 2025, with a similar pace of quarterly revenue anticipated in 2026.
Sample Management Business Revenue: Revenue from Sample Management products is expected to be in the high $30 million range for 2025, approximately flat compared to 2024, excluding the decline in orders from a large consumer genetics customer.
Sample Management Business Growth Outlook: The business is expected to return to growth in 2026 and beyond, driven by genomic end segments, clinical adoption of precision medicine, and advancements in sequencing technologies.
Product Innovation and FDA Submissions: Clinical trial data for Colli-Pee urine collection for STI indications and Sherlock Molecular Diagnostics Rapid Test platform for CT/NG are planned for submission to the FDA by late 2025 or early 2026.
Revenue Guidance for Q4 2025: Revenue is projected to be between $25 million and $28 million, with less than $100,000 from COVID-19 testing revenues.
Gross Margin Guidance for Q4 2025: Gross margin percentage is expected to be in the low 40% range, slightly lower than Q3 due to seasonality and a higher mix of international revenue.
Operating Expenses for Q4 2025: Core operating expenses are expected to be approximately $20 million, with an additional $10 million for innovation investments, including $7 million to $8 million for the Sherlock platform.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Repurchase Program: We deployed $5 million during the third quarter to repurchase approximately 1.5 million shares of our common stock.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Could you discuss the BioMedomics acquisition and what attracted you to that asset?
A:The BioMedomics acquisition is a strategic fit for the company's portfolio, particularly in underserved markets like Africa and Latin America. It focuses on low-cost rapid diagnostic tests for pressing healthcare challenges, such as sickle cell disease, HIV, and HCV. The company has been in discussions with BioMedomics for years and sees this as a promising opportunity for smart capital deployment. The deal structure includes a small upfront payment with contingent considerations based on milestones over 3-5 years, aiming for strong returns on invested capital and breakeven cash flow.
Q:Can you highlight some of the factors affecting gross margins and any lingering costs from the in-sourcing completed in Q2?
A:Gross margins were better than expected due to lower scrap rates, thanks to operational efficiencies and automation. OpEx was in line with expectations, with spending focused on innovation, particularly the Sherlock CT/NG clinical trial submission. There was also a mix benefit in Q3, but Q4 margins are expected to be slightly lower due to seasonality and a higher mix of international revenue, which typically has lower margins.
Q:Review of Unclear Management Responses
A:None of the questions were avoided or lacked clarity. The management provided detailed and direct answers to all questions.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
BioMedomics OTI
BioMedomics tuck
CT NG
Colli Pee
Diagnostics mid
ENDO project
Home
International Diagnostics
RUO market
STI indication
Sample end
Sherlock
Sickle SCAN
adoption Sickle
agreement BioMedomics
cell disease
cell testing
decline
genetics
government shutdown
health program
pattern
percentage
platform assay
stabilization
stage
study
test cell
trial
urine collection
value
OSUR Transcript
OraSure Technologies, Inc. (OSUR) Q1 2026 Earnings Call Transcript
Positive5-6
The earnings call indicates strong financial performance with a 10% YoY revenue increase and improved gross margins. Net income shifted from a loss to a profit, and cash flow from operations increased significantly. Despite potential risks highlighted in forward-looking statements, the financial health and positive outlook on product demand suggest a positive market reaction.
OraSure Technologies, Inc. (OSUR) Q4 2025 Earnings Call Transcript
Unknown2-25
The earnings call presents a mixed picture: strong financial metrics with improved gross margins and a share repurchase program, yet weak guidance for 2025 with declining revenues in key segments. The Q&A reveals some uncertainties in product launches and funding stabilization. While there are positive signs like potential growth in 2026 and successful market expansion, the lack of clear guidance and current revenue declines balance these out, leading to a neutral sentiment prediction.
OraSure Technologies, Inc. (OSUR) Q3 2025 Earnings Call Transcript
Unknown11-5
The earnings call presents a mixed outlook. While revenue and margins are stable, significant challenges include declining international diagnostics revenue and economic uncertainties. The positive aspects include operational efficiencies, innovation investments, and a share repurchase program. The Q&A provides a strategic fit for acquisitions and improved gross margins, but risks like regulatory approvals and market conditions persist. Overall, the sentiment is balanced, suggesting a neutral stock price movement.
OraSure Technologies, Inc. (OSUR) Q2 2025 Earnings Call Transcript
Unknown8-5
The earnings call presents a mixed picture: strong core revenue and gross margin improvements are positive, but significant challenges include revenue decline from a major customer, NIH funding cuts, and high operating losses. The Q&A reveals uncertainties in revenue guidance and manufacturing transition impacts. The share repurchase is a slight positive, but overall, the sentiment is neutral due to balanced positive and negative factors. The lack of clear guidance and uncertainties in key areas temper potential optimism.
OSUR Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
